Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Suzhou Alphamab to Start China Trial of Bispecific HER2 Inhibitor

publication date: Apr 16, 2018

Suzhou Alphamab was granted CFDA approval of an IND for its leading bispecific program, a HER2 inhibitor, which will be tested in patients with HER2 positive breast and gastric cancers. According to Alphamab, KN026 showed excellent binding affinity, efficacy, safety, and PK in pre-clinical tests. Initially, the company plans to start a Phase I trial in China, followed by clinical development in the US and Japan. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China